All In Biotech

Drug Trial Radar · NCT02774044

Efficacy and Safety of Goat Lung Surfactant for the Treatment of Respiratory Distress Syndrome in Preterm Neonates

Evaluating the Efficacy and Safety of an Innovative and Affordable Goat Lung Surfactant for the Treatment of Respiratory Distress Syndrome in Preterm Neonates: a Multi-site Randomized Clinical Trial

Last checked: Nov 19, 2026Latest source record: May 17, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 900 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

900

Planned (sponsor's estimate)

Start

Jun 2016

Primary completion

Feb 2019

Study completion May 2019

Sponsor

Lead sponsor
Ramesh K AgarwalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Maulana Azad Medical College, New Delhi; Lady Hardinge Medical College; Chacha Nehru Bal Chikitsalya, Delhi; Post Graduate Institute of Medical Education and Research, Chandigarh; King Edward Memorial Hospital, Mumbai; Lokmanya Tilak Municipal General Hospital, Mumbai; Institute of Child health and Hospital for Children, Chennai; Jawaharlal Institute of Postgraduate Medical Education & Research; All India Institute of Medical Sciences; St Johns Medical College Hospital, Bangalore, India; King Edward Memorial Hospital, Pune; Government Medical College, Chandigarh; Wellcome Trust
First posted
May 17, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 26 weeks, up to 32 weeks
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the efficacy and safety of Cadisurf (goat lung surfactant extract) as compared to Survanta (beractant) in the treatment of respiratory distress syndrome in preterm neonates (with gestation of 26 to 32 weeks).

Conditions

  • Respiratory Distress Syndrome

Interventions

  • CadisurfDrug

    Cadisurf Intratracheal suspension is a sterile, non-pyrogenic pulmonary surfactant intended for intratracheal use only. It is a natural lung extract containing phospholipids and surfactant-associated proteins. The resulting composition provides 25 mg/mL phospholipids and less than 1.0 mg/ml protein. It is suspended in 0.9% sodium chloride solution. Cadisurf contains no preservatives. Each ml of Cadisurf contains 25 mg of phospholipids. It is a creamy white suspension supplied in single-use glass vials containing 8 mL (200 mg phospholipids).

  • SurvantaDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. BPD free survivalTime frame: 36 weeks post menstrual age

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.